We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$247M
AUM Growth
+$69.9M
Cap. Flow
+$70.2M
Cap. Flow %
28.45%
Top 10 Hldgs %
43.11%
Holding
96
New
14
Increased
43
Reduced
12
Closed
25

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.72M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$6.46M
3
IMGN
Immunogen Inc
IMGN
+$5.37M
4
BLU
BELLUS Health Inc.
BLU
+$4.88M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.23M

Top Sells

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$5.24M
2
NXTC icon
NextCure
NXTC
+$3.68M
3
ARVN icon
Arvinas
ARVN
+$3.06M
4
INSM icon
Insmed
INSM
+$2.11M
5
ERAS icon
Erasca
ERAS
+$1.98M

Sector Composition

Rank Sector Weight
1 Healthcare 84.37%
2 Financials 5.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
76
Cabaletta Bio
CABA
$444M
– –
-42,022
Closed -$511K
CRIS icon
77
Curis
CRIS
$9.67M
– –
-155
Closed -$369K
HELP
78
Cybin Inc
HELP
$505M
– –
-6,579
Closed -$549K
ERAS icon
79
Erasca
ERAS
$6.48B
– –
-93,122
Closed -$1.98M
FULC icon
80
Fulcrum Therapeutics
FULC
$248M
– –
-185,691
Closed -$5.24M
GH icon
81
Guardant Health
GH
$20.2B
– –
-4,218
Closed -$527K
GYRE icon
82
Gyre Therapeutics
GYRE
$648M
– –
-1,333
Closed -$41K
IVVD icon
83
Invivyd
IVVD
$171M
– –
-5,000
Closed -$211K
KROS icon
84
Keros Therapeutics
KROS
$202M
– –
-10,000
Closed -$396K
NTLA icon
85
Intellia Therapeutics
NTLA
$1.55B
– –
-4,950
Closed -$664K
RAPT
86
DELISTED
RAPT Therapeutics
RAPT
– –
-1,475
Closed -$366K
ZNTL icon
87
Zentalis Pharmaceuticals
ZNTL
$350M
– –
-23,855
Closed -$1.59M
RNLX
88
DELISTED
Renalytix plc American Depositary Shares
RNLX
– –
-37,000
Closed -$742K
SURF
89
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-50,000
Closed -$379K
ISEE
90
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-30,000
Closed -$487K
EVLO
91
PUT
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-3,085
Closed -$434K
AYLA
92
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
– –
-40,956
Closed -$464K
CCXI
93
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-139,200
Closed -$2.38M
ARNA
94
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-18,581
Closed -$1.11M
DRNA
95
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-31,040
Closed -$626K
ADMS
96
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-288,042
Closed -$1.41M
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Silverarc Capital Management held 96 positions worth $247M, up 40% from $177M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Silverarc Capital Management deployed $70.2M of net new capital in Q4 2021, opening 14 new positions and adding to 43 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was NextCure, an estimated $3.68M trimmed.

  • Silverarc Capital Management's largest Q4 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.
  • Silverarc Capital Management added most to Immunogen Inc in Q4 2021, an estimated $5.37M increase.
  • Silverarc Capital Management's biggest Q4 2021 reduction was NextCure, cutting an estimated $3.68M.
  • Silverarc Capital Management fully exited Fulcrum Therapeutics in Q4 2021, selling an estimated $5.24M.
  • Silverarc Capital Management's ten largest holdings make up 43% of its $247M portfolio in Q4 2021.
  • Silverarc Capital Management opened 14 new positions and closed 25 in Q4 2021.
  • Silverarc Capital Management's portfolio value rose 40% quarter-over-quarter to $247M.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.